Report
FDA warns Fresenius unit Kabi over ‘significant violations’ at Illinois facility
Bloomberg reports that Kabi, Fresenius SE’s generic drugs unit, received an FDA warning letter concerning a facility in Illinois.
TLDR
Bloomberg reports that the US Food and Drug Administration sent Fresenius SE’s generic drugs unit Kabi a warning letter citing “significant violations” at a facility in Illinois.
Combined views
21.7K
1 Source, first seen 6h ago
6 likes